TD139; TD-139; 1450824-22-2; olitigaltin; TD 139; GB0139; GB-0139; Olitigaltin [USAN]; 60Y0GUO72B; (2S,3R,4S,5R,6R)-4-[4-(3-Fluorophenyl)triazol-1-yl]-2-[(2S,3R,4S,5R,6R)-4-[4-(3-fluorophenyl)triazol-1-yl]-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanyl-6-(hydroxymethyl)oxane-3,5-diol; 3-Deoxy-3-[4-(3-Fluorophenyl)-1h-1,2,3-Triazol-1-Yl]-Beta-D-Galactopyranosyl 3-Deoxy-3-[4-(3-Fluorophenyl)-1h-1,2,3-Triazol-1-Yl]-1-Thio-Beta-D-Galactopyranoside; (2R,2'R,3R,3'R,4S,4'S,5R,5'R,6S,6'S)-6,6'-Thiobis(4-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)tetrahydro-2H-pyran-3,5-diol); UNII-60Y0GUO72B; TD2; OLITIGALTIN [INN]; Gal-3 Inhibitor GB0139; Galectin-3 Inhibitor GB0139; CHEMBL4297442; SCHEMBL15657269; TD 139 [WHO-DD]; GTPL12148; EX-A1688; BDBM50581762; WHO 12032; ZINC208938373; CS-6265; DB12895; GB 0139; AC-35516; beta-D-Galactopyranoside, 3-deoxy-3-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-beta-D-galactopyranosyl 3-deoxy-3-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-1-thio-; BS-15429; BT173009; HY-19940; C72753; A857944; Q27263259; bis-(3-deoxy-3-(3-fluorophenyl-1h-1,2,3-triazol-1-yl)-beta-d-galactopyranosyl)-sulfane; .BETA.-D-GALACTOPYRANOSIDE, 3-DEOXY-3-(4-(3-FLUOROPHENYL)-1H-1,2,3-TRIAZOL-1-YL)-.BETA.-D-GALACTOPYRANOSYL 3-DEOXY-3-(4-(3-FLUOROPHENYL)-1H-1,2,3-TRIAZOL-1-YL)-1-THIO-; 3,3'-DIDEOXY-3,3'-BIS-(4-(3-FLUOROPHENYL)-1H-1,2,3-TRIAZOL-1-YL)-1,1'-SULFANEDIYL-DI-.BETA.- D-GALACTOPYRANOSIDE; BIS(3-DEOXY-3-(3-FLUOROPHENYL-1H-1,2,3-TRIAZOL-1-YL)-.BETA.-D-GALACTOPYRANOSYL)SULFANE